20-Feb-2026
TipRanks (Wed, 18-Feb 6:41 AM ET)
TipRanks (Tue, 17-Feb 10:10 AM ET)
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011
Business Wire (Tue, 17-Feb 7:00 AM ET)
Market Chameleon (Mon, 26-Jan 4:03 AM ET)
Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer
Business Wire (Mon, 26-Jan 7:00 AM ET)
Market Chameleon (Thu, 22-Jan 6:21 AM ET)
Business Wire (Thu, 22-Jan 7:00 AM ET)
Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study
Business Wire (Tue, 23-Dec 4:05 PM ET)
Business Wire (Mon, 1-Dec 4:05 PM ET)
Market Chameleon (Mon, 24-Nov 4:15 AM ET)
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Janux Therapeutics trades on the NASDAQ stock market under the symbol JANX.
As of February 20, 2026, JANX stock price declined to $13.08 with 761,845 million shares trading.
JANX has a beta of 1.16, meaning it tends to be more sensitive to market movements. JANX has a correlation of 0.05 to the broad based SPY ETF.
JANX has a market cap of $786.03 million. This is considered a Small Cap stock.
Last quarter Janux Therapeutics reported $10 million in Revenue and -$.39 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.22.
In the last 3 years, JANX traded as high as $71.71 and as low as $5.65.
The top ETF exchange traded funds that JANX belongs to (by Net Assets): XBI, VTI, IWM, VXF, IBB.
JANX has underperformed the market in the last year with a return of -64.8%, while the SPY ETF gained +14.1%. In the last 3 month period, JANX fell short of the market, returning -54.2%, while SPY returned +6.0%. However, in the most recent 2 weeks JANX has outperformed the stock market by returning +0.1%, while SPY returned -0.2%.
JANX support price is $12.88 and resistance is $13.96 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that JANX shares will trade within this expected range on the day.
